"Consider a year ago we had one product with potential but still tainted by the harsh label after the vascular side effects debacle. Now we have that same product but about to have a much better label which will translate to a lot more revenue. But, additionally, we have a second product which will be BIC and a billion dollar med within a short time. Plus, a third molecule with the potential to be bigger than the other two within a few years. Plus, other molecules in the lab with God knows what potential."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.